| Change from baseline | Repeated measures two-way ANOVA | |||||||
---|---|---|---|---|---|---|---|---|---|
 | Week 4 | Week 8 | Week 12 | Group | Time | Interaction | |||
 | Mean | SD | Mean | SD | Mean | SD | |||
Anger-hostility (AH) | |||||||||
 Placebo | 1.95 | 4.76 | 1.55 | 6.02 | 1.75 | 5.29 | 0.022 | 0.706 | 0.472 |
 CLE | −0.69* | 5.37 | 0.16 | 6.01 | −1.10* | 5.40 | |||
Confusion-bewilderment (CB) | |||||||||
 Placebo | −0.10 | 4.80 | 0.82 | 6.16 | 0.00 | 4.54 | 0.885 | 0.956 | 0.367 |
 CLE | −0.64 | 4.37 | 0.71 | 5.93 | −0.97 | 4.49 | |||
Depression-dejection (DD) | |||||||||
 Placebo | 0.90 | 4.42 | 0.53 | 4.86 | 0.35 | 5.37 | 0.312 | 0.287 | 0.285 |
 CLE | −0.64 | 4.37 | 0.71 | 5.93 | −0.97 | 4.49 | |||
Fatigue-inertia (FI) | |||||||||
 Placebo | −0.03 | 4.81 | −0.70 | 4.87 | −0.25 | 5.23 6.82 | 0.900 | 0.433 | 0.294 |
 CLE | −0.05 | 6.73 | 0.11 | 7.05 | −1.46 | ||||
Tension-anxiety (TA) | |||||||||
 Placebo | −1.70 | 7.77 | −2.58 | 6.00 | −1.48 | 6.99 | 0.331 | 0.469 | 0.108 |
 CLE | 0.10 | 7.36 | −0.18 | 7.00 | −1.90 | 6.69 | |||
Vigor-activity (VA) | |||||||||
 Placebo | 1.58 | 7.19 | 1.08 | 8.23 | 2.10 | 8.74 | 0.141 | 0.184 | 0.841 |
 CLE | −0.23 | 5.94 | −1.55 | 6.20 | 0.13 | 7.81 | |||
Friendliness (F) | |||||||||
 Placebo | 0.05 | 8.19 | −0.63 | 9.62 | − 0.33 | 8.46 | 0.983 | 0.706 | 0.989 |
 CLE | 0.00 | 7.19 | −0.45 | 7.83 | −0.15 | 8.79 | |||
Total mood disturbance (TMD) | |||||||||
 Placebo | −0.05 | 4.62 | −0.65 | 4.15 | −0.28 | 3.89 | 0.894 | 0.374 | 0.109 |
 CLE | −0.23 | 5.04 | 0.68 | 6.54 | −1.08 | 5.48 |